N/A N=6 Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe
Barrett's Esophagus
Primary: Number of Participants With Tolerability of the Procedure — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Genetic Effects on Dopamine Response to an Opiate
Polymorphism-Genetic · Pain · Addiction
Primary: 11C Raclopride Binding Potential in Caudate — 3.25; 3.45 mCi/ml
Phase 2 N=300 A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)
Postherpetic Neuralgia
Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Average Numeric Rating Scale (NRS) Pain Scores Using a Mixed Model for Repeated Measures — 5.37; 5.60…
Phase 4 N=1,013 A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Hepatitis C, Chronic
Primary: Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment — 15.7 Percentage of participants
Phase 3 N=1,902 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Asthma
Primary: Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population — 0.871; 0.456; 0.970; 0.524 Exacerbation per…
Phase 3 N=210 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Asthma
Primary: Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control — 41.85; 70.09 Percentage reduction from baseline — p=<…
Phase 3 N=769 Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
HIV-1
Primary: Percentage of Participants Achieving Plasma HIV-1 RNA <50 Copies/mL at Week 48 — 83.8; 79.9 Percentage of participants
Phase 2 N=2 Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
Attention Deficit Hyperactivity Disorder (ADHD) · Deficient Emotional Self-Regulation (DESR)
Primary: Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale — -7; -33 T-Score
N/A N=23 Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain
Cervical Radiculopathy
Primary: Upper Limb Neurodynamic Tesnion (UNLT) Range of Motion — 4.60; 16.00 degrees
Phase 2 N=52 Placebo Controlled Trial of Dextromethorphan in Rett Syndrome
Rett Syndrome
Primary: Change in Mullen; Visual Reception Sub-scale Scores, Pre- and Post-Intervention — 5.45; 6.61; 6.64; 6.57 score on a scale — p=.211
Phase 1 N=20 A Study of LY2216684 in Healthy Females
Depressive Disorder, Major
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Ethinyl Estradiol and Norelgestromin — 79.0; 80.9; 1438; 1574 picograms/milliliter (pg/mL)
Phase 1 N=48 A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
Major Depressive Disorder
Primary: Maximum, Minimum and Average Changes in Heart Rate — 33.4; 15.7; 35.7; 31.1 beats per minute (bpm)
N/A N=114 A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
Stress Urinary Incontinence
Primary: Change in 1-hour Pad Weight Test From Baseline to 24 Month Follow-up — 48.7; 6.6 grams
Phase 1 N=9 A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Advanced Solid Tumors
Primary: Number of Participants With Adverse Events (AEs) or Deaths — 2; 3; 2; 0 Participants
Phase 4 N=111 Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Number of Patients Who Have Had Carpal Tunnel Release Surgery on the Study Hand — 31; 34; 36 Participants